A detailed history of Black Rock Inc. transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 333,171 shares of PLX stock, worth $393,141. This represents 0.0% of its overall portfolio holdings.

Number of Shares
333,171
Previous 3,310,517 89.94%
Holding current value
$393,141
Previous $4.17 Million 90.67%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$1.1 - $1.32 $3.28 Million - $3.93 Million
-2,977,346 Reduced 89.94%
333,171 $389,000
Q1 2024

May 10, 2024

SELL
$1.22 - $1.82 $179,604 - $267,934
-147,217 Reduced 4.26%
3,310,517 $4.17 Million
Q4 2023

Feb 13, 2024

BUY
$1.34 - $1.85 $378,244 - $522,203
282,272 Added 8.89%
3,457,734 $6.15 Million
Q3 2023

Nov 13, 2023

BUY
$1.49 - $2.02 $796,391 - $1.08 Million
534,491 Added 20.24%
3,175,462 $5.27 Million
Q2 2023

Aug 11, 2023

BUY
$2.0 - $3.36 $5.05 Million - $8.48 Million
2,524,828 Added 2173.9%
2,640,971 $5.28 Million
Q1 2023

May 12, 2023

BUY
$1.37 - $2.16 $19,522 - $30,780
14,250 Added 13.99%
116,143 $243,000
Q4 2022

Feb 13, 2023

BUY
$1.0 - $1.37 $3,130 - $4,288
3,130 Added 3.17%
101,893 $139,000
Q3 2022

Nov 14, 2022

SELL
$1.03 - $1.24 $2,873 - $3,459
-2,790 Reduced 2.75%
98,763 $103,000
Q2 2022

Aug 12, 2022

SELL
$1.02 - $1.56 $7,658 - $11,712
-7,508 Reduced 6.88%
101,553 $111,000
Q1 2022

May 12, 2022

SELL
$0.81 - $1.17 $4,322 - $6,244
-5,337 Reduced 4.67%
109,061 $116,000
Q4 2021

Feb 10, 2022

SELL
$0.81 - $1.33 $4,177 - $6,858
-5,157 Reduced 4.31%
114,398 $95,000
Q3 2021

Nov 09, 2021

SELL
$1.31 - $1.87 $3,856 - $5,505
-2,944 Reduced 2.4%
119,555 $159,000
Q2 2021

Aug 11, 2021

BUY
$1.86 - $6.22 $227,848 - $761,943
122,499 New
122,499 $234,000

Others Institutions Holding PLX

About Protalix BioTherapeutics, Inc.


  • Ticker PLX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,753,400
  • Market Cap $58.7M
  • Description
  • Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...
More about PLX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.